海外の治験の状況「1」での検索結果
2657件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- 207966 or "ATLAS-2M" is a study to compare two drugs called Cabotegravir and Rilpivirine when given as long acting injections either every 8 weeks or every 4 weeks in adults with HIV.
- Human Immunodeficiency Virus type 1 (HIV-1) MedDRA version: 20.1 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Canada, France, Germany, Italy, Korea, Democratic People's Republic of, Mexico, Russian Federation, South Africa, Spain, Sweden, United States
- 2017-10-18
Not Recruiting
- Phase 2 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC
- First-line treatment of metastatic NSCLC MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-10-04
Authorised
- 207966 or "ATLAS-2M" is a study to compare two drugs called Cabotegravir and Rilpivirine when given as long acting injections either every 8 weeks or every 4 weeks in adults with HIV.
- Human Immunodeficiency Virus type 1 (HIV-1) MedDRA version: 20.0 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000020183 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Canada, France, Germany, Italy, Korea, Democratic People's Republic of, Mexico, Russian Federation, South Africa, Spain, Sweden, United States
- 2017-09-18
Authorised
- Clinical trial using GSK525762 in combination with fulvestrant in subjects with breast cancer.
- ER-positive Breast Cancer MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Korea, Republic of, Spain, United Kingdom, United States
- 2017-01-03
Not recruiting
- Effect of Nitric Oxide Donors on Uterine and Subendometrial Blood Flow in Patients With Unexplained Infertility
- Polycystic Ovary Syndrome;Infertility, Female;Polycystic Ovary Syndrome;Infertility, Female;Polycystic Ovary Syndrome;Infertility, Female
- Egypt
- 2018-03-19
Authorised
- Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC
- First-line treatment of metastatic NSCLC MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-03-12
Not Recruiting
- Worms and human immunodeficiency virus (HIV) Interaction Study - Epidemiology component
- Human immunodeficiency virus-1 (HIV-1) infection/helminth infections Infections and Infestations Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases
- Tanzania
- 2009-08-19
Not Recruiting
- BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Phase III Study in Previously untreated Patients with Unresectable Stage IIIC or Stage IV Melanoma with V600E BRAF mutation Receiving Vemurafenib (RO5185426) or Dacarbazine. - BRIM 3
- First-line therapy for adult patients with histologically confirmed metastatic melanoma (unresectable Stage IIIC or Stage IV) harbouring the V600E positive mutation MedDRA version: 17.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Germany, Israel, Italy, Netherlands, New Zealand, Sweden, Switzerland, United Kingdom, United States
- 2009-10-29
Not recruiting
- A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
- Dilated Cardiomyopathy;Dilated Cardiomyopathy;Dilated Cardiomyopathy
- Australia
- 2017-02-16
Not Recruiting
- Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer
- Women with platinum resistant/refractory ovarian cancers who are about to start 2nd or subsequent line chemotherapy
- Australia, Europe, Japan, North America
- 2013-03-15
Authorised
- 201584 or “FLAIR” is a study to compare two drugs (called Cabotegravir and Rilpivirine, as oral tablets followed by long-acting injections) to a single tablet regimen containing 3 HIV drugs (called Triumeq)
- Human Immunodeficiency Virus type 1 (HIV-1) MedDRA version: 19.0 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Canada, France, Germany, Italy, Japan, Netherlands, Russian Federation, South Africa, Spain, United Kingdom, United States
- 2016-08-05
Authorised
- A Phase III study to compare two drugs (called Cabotegravir and Rilpivirine, as oral tablets followed by long-acting injections) to current HIV regimens containing three drugs
- Human Immunodeficiency Virus type 1 (HIV-1) MedDRA version: 19.0 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Canada, France, Germany, Italy, Korea, Democratic People's Republic of, Mexico, Russian Federation, South Africa, Spain, Sweden, United States
- 2016-08-05
Authorised
- Phase 2 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC
- First-line treatment of metastatic NSCLC MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-11-22
Recruiting
- International Collaborative Gaucher Group (ICGG) Gaucher Registry
- Cerebroside Lipidosis Syndrome;Glucocerebrosidase Deficiency Disease;Glucosylceramide Beta-Glucosidase Deficiency Disease;Gaucher Disease
- Australia, Brazil, Canada, China, Egypt, France, Hong Kong, Italy, Japan, Korea, Republic of, Malaysia, Peru, Philippines, Singapore, Slovakia, South Africa, Sweden, Thailand, United States
- 2006-07-12
Recruiting
- A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers
- Inflammatory Bowel Disease;Ulcerative colitis;Crohn's Disease; Inflammatory Bowel Disease Ulcerative colitis Crohn's Disease;Inflammatory and Immune System - Autoimmune diseases;Oral and Gastrointestinal - Crohn's disease
- Australia
- 2018-07-19
Recruiting
- Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute
- Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, United States
- 2017-08-30
Not Recruiting
- A Phase III Study of STI571 Versus Interferon-a (IFN-a) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
- Chronic Myelogenous Leukemia;C92.1 - Chronic myeloid leukaemia [CML], BCR/ABL-positive
- Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, United States
- 2012-05-09
Authorised
- A study of Iclusig (ponatinib), an oral kinase-inhibitor treatment administered, by standard dose or reduced doses, for patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) who no longer benefit from, or who have an abnormal gene (T315I positive) marker for resistance to other kinase-inhibitor treatments.
- Chronic Phase Chronic Myeloid Leukemia MedDRA version: 20.0 Level: LLT Classification code 10054352 Term: Chronic phase chronic myeloid leukemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-07-07
- A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, PHASE III STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF FULVESTRANT (FASLODEX TM) 500 MG WITH ANASTROZOLE (ARIMIDEX TM) 1 MG AS HORMONAL TREATMENT FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE NOT PREVIOUSLY BEEN TREATED WITH ANY HORMONAL THERAPY (FALCON)
- Argentina, Brazil, Canada, Czech Republic, India, Italy, Japan, Mexico, Peru, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kindgdom, United States
- 2013-02-22
Not recruiting
- A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
- Chronic Hepatitis C;Human Immunodeficiency Virus;Chronic Hepatitis C;Human Immunodeficiency Virus;Chronic Hepatitis C;Human Immunodeficiency Virus;Chronic Hepatitis C;Human Immunodeficiency Virus
- Australia, France, Germany, Italy, Portugal, Spain, United Kingdom
- 2013-01-31